|
시장보고서
상품코드
2151843
혈관화 오가노이드 시장 규모, 점유율, 동향 분석 보고서 : 제품·서비스별, 혈관화 기법별, 오가노이드 유형별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Vascularized Organoids Market Size, Share & Trends Analysis Report By Products & Services, By Vascularization Approach, By Organoid Type, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
혈관화 오가노이드 시장 요약
전 세계 혈관화 오가노이드 시장 규모는 2025년에 9,430만 달러로 평가되며, 2026년 1억 2,350만 달러에서 2033년까지 9억 830만 달러로 확대될 것으로 예상되며, 2026년부터 2033년까지의 연평균 성장률(CAGR)은 33.0%에 달할 것으로 전망됩니다.
북미가 시장을 주도하고 있으며, 2025년에는 43.0%라는 최대 매출 점유율을 차지했습니다. 시장의 성장은 신약 개발, 질환 모델링, 재생의학, 맞춤형 의료 분야에서 혈관화 오가노이드의 채택 확대는 물론, 줄기세포 기술, 3D 바이오프린팅, 혈관화 기술 및 오가노이드 배양 시스템의 발전에 의해 주도되고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법 및 범위
제2장 요약
제3장 시장 : 변수, 동향, 범위
- 시장 계보 전망
- 시장 역학
- 업계 분석 도구
제4장 제품·서비스 사업 분석
- 혈관화 오가노이드 시장 : 제품·서비스 변동 분석
- 키트, 시약, 배지
- 장비·플랫폼
- 서비스
제5장 혈관화 기법의 비즈니스 분석
- 혈관화 오가노이드 시장 : 혈관화 기법의 변동 분석
- 정적 체외법
- 관류/마이크로유체 시스템
- 생체 내/이식을 기반으로 한 기법
- 바이오프린팅을 통한 구조체
제6장 오가노이드 유형의 비즈니스 분석
- 혈관화 오가노이드 시장 : 오가노이드 유형별 변동 분석
- 간
- 뇌
- 심장
- 신장
- 폐
- 기타
제7장 용도별 비즈니스 분석
- 혈관화 오가노이드 시장 : 용도별 동향 분석
- 신약 개발
- 질환 모델링
- 독성 시험
- 정밀/맞춤형 의료
- 재생의학 및 이식
제8장 최종 용도별 비즈니스 분석
- 혈관화 오가노이드 시장 : 최종 용도별 동향 분석
- 제약·바이오기술 기업
- 학술 연구 기관
- CRO
제9장 지역별 비즈니스 분석
- 혈관화 오가노이드 시장 점유율 : 지역별(2025년 및 2033년)
- 북미
- 북미 혈관화 오가노이드 시장(2021-2033년)
- 미국
- 캐나다
- 멕시코
- 유럽
- 유럽의 혈관화 오가노이드 시장(2021-2033년)
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 아시아태평양 혈관화 오가노이드 시장(2021-2033년)
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
- 라틴아메리카
- 라틴아메리카 혈관화 오가노이드 시장(2021-2033년)
- 브라질
- 아르헨티나
- 중동 및 아프리카
- MEA의 혈관화 오가노이드 시장(2021-2033년)
- 남아프리카
- 사우디아라비아
- UAE
- 쿠웨이트
제10장 경쟁 현황
- 기업 분류
- 기업 점유율 및 포지셔닝 분석, 2025년
- 전략 매핑
- 기업 개요 목록
- Thermo Fisher Scientific Inc.
- Corning Incorporated
- STEMCELL Technologies
- Emulate, Inc.
- CN Bio Innovations
- MIMETAS
- InSphero AG
- TissUse GmbH
- AIM Biotech
- Vivodyne
Vascularized Organoids Market Summary
The global vascularized organoids market size was valued at USD 94.3 million in 2025 and is projected to grow from USD 123.5 million in 2026 to USD 908.3 million by 2033, at a CAGR of 33.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.0% in 2025. Market growth is driven by increasing adoption of vascularized organoids in drug discovery, disease modeling, regenerative medicine, and personalized medicine, alongside advancements in stem cell technologies, 3D bioprinting, vascularization techniques, and organoid culture systems.
Global Vascularized Organoids Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global vascularized organoids market on the basis of products & services, vascularization approach, organoid type, application, end-use, and region:
- Products & Services Outlook (Revenue, USD Million, 2021 - 2033)
- Kits, Reagents & Media
- Instruments & Platforms
- Services
- Vascularization Approach Outlook (Revenue, USD Million, 2021 - 2033)
- Static In Vitro Methods
- Perfused / Microfluidic Systems
- In Vivo / Transplantation-Based Methods
- Bioprinted Constructs
- Organoid Type Outlook (Revenue, USD Million, 2021 - 2033)
- Liver
- Brain
- Cardiac
- Kidney
- Lung
- Other
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Drug Discovery
- Disease Modeling
- Toxicity Testing
- Precision / Personalized Medicine
- Regenerative Medicine & Transplantation
- End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- CROs
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Products & Services Segment
- 1.1.1.2. Vascularization Approach Segment
- 1.1.1.3. Organoid Type Segment
- 1.1.1.4. Application Segment
- 1.1.1.5. End Use Segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis:
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. List of Secondary Sources
- 1.9.3. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising Prevalence of Chronic Diseases and Cancer
- 3.2.1.2. Growing Adoption in Drug Discovery and Toxicity Testing
- 3.2.1.3. Advancements in Stem Cell And 3D Cell Culture Technologies
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Cost of Organoid Development and Maintenance
- 3.2.2.2. Complexity of Vascularization and Organoid Culture
- 3.2.3. Market Opportunities Analysis
- 3.2.4. Market Challenges Analysis
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Economic landscape
- 3.3.2.5. Legal landscape
- 3.3.1. Porter's Five Forces Analysis
Chapter 4. Products & Services Business Analysis
- 4.1. Segment Dashboard
- 4.2. Vascularized Organoids Market: Products & Services Movement Analysis
- 4.3. Kits, Reagents & Media
- 4.3.1. Kits, Reagents & Media Market, 2021 - 2033 (USD Million)
- 4.4. Instruments & Platforms
- 4.4.1. Instruments & Platforms Market, 2021 - 2033 (USD Million)
- 4.5. Services
- 4.5.1. Services Market, 2021 - 2033 (USD Million)
Chapter 5. Vascularization Approach Business Analysis
- 5.1. Segment Dashboard
- 5.2. Vascularized Organoids Market: Vascularization Approach Movement Analysis
- 5.3. Static In Vitro Methods
- 5.3.1. Static In Vitro Methods Market, 2021 - 2033 (USD Million)
- 5.4. Perfused / Microfluidic Systems
- 5.4.1. Perfused / Microfluidic Systems Market, 2021 - 2033 (USD Million)
- 5.5. In Vivo / Transplantation-Based Methods
- 5.5.1. In Vivo / Transplantation-Based Methods Market, 2021 - 2033 (USD Million)
- 5.6. Bioprinted Constructs
- 5.6.1. Bioprinted Constructs Market, 2021 - 2033 (USD Million)
Chapter 6. Organoid Type Business Analysis
- 6.1. Segment Dashboard
- 6.2. Vascularized Organoids Market: Organoid Type Movement Analysis
- 6.3. Liver
- 6.3.1. Liver Market, 2021 - 2033 (USD Million)
- 6.4. Brain
- 6.4.1. Brain Market, 2021 - 2033 (USD Million)
- 6.5. Cardiac
- 6.5.1. Cardiac Market, 2021 - 2033 (USD Million)
- 6.6. Kidney
- 6.6.1. Kidney Market, 2021 - 2033 (USD Million)
- 6.7. Lung
- 6.7.1. Lung Market, 2021 - 2033 (USD Million)
- 6.8. Other
- 6.8.1. Other Market, 2021 - 2033 (USD Million)
Chapter 7. Application Business Analysis
- 7.1. Segment Dashboard
- 7.2. Vascularized Organoids Market: Application Movement Analysis
- 7.3. Drug Discovery
- 7.3.1. Drug Discovery Market, 2021 - 2033 (USD Million)
- 7.4. Disease Modeling
- 7.4.1. Disease Modeling Market, 2021 - 2033 (USD Million)
- 7.5. Toxicity Testing
- 7.5.1. Toxicity Testing Market, 2021 - 2033 (USD Million)
- 7.6. Precision / Personalized Medicine
- 7.6.1. Precision / Personalized Medicine Market, 2021 - 2033 (USD Million)
- 7.7. Regenerative Medicine & Transplantation
- 7.7.1. Regenerative Medicine & Transplantation Market, 2021 - 2033 (USD Million)
Chapter 8. End Use Business Analysis
- 8.1. Segment Dashboard
- 8.2. Vascularized Organoids Market: End Use Movement Analysis
- 8.3. Pharmaceutical & Biotechnology Companies
- 8.3.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
- 8.4. Academic & Research Institutes
- 8.4.1. Academic & Research Institutes Market, 2021 - 2033 (USD Million)
- 8.5. CROs
- 8.5.1. CROs Market, 2021 - 2033 (USD Million)
Chapter 9. Regional Business Analysis
- 9.1. Vascularized Organoids Market Share By Region, 2025 & 2033
- 9.2. North America
- 9.2.1. North America Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.2.2. U.S.
- 9.2.2.1. Key Country Dynamics
- 9.2.2.2. Competitive Scenario
- 9.2.2.3. Regulatory Framework
- 9.2.2.4. U.S. Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.2.3. Canada
- 9.2.3.1. Key Country Dynamics
- 9.2.3.2. Competitive Scenario
- 9.2.3.3. Regulatory Framework
- 9.2.3.4. Canada Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.2.4. Mexico
- 9.2.4.1. Key Country Dynamics
- 9.2.4.2. Competitive Scenario
- 9.2.4.3. Regulatory Framework
- 9.2.4.4. Mexico Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3. Europe
- 9.3.1. Europe Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3.2. UK
- 9.3.2.1. Key Country Dynamics
- 9.3.2.2. Competitive Scenario
- 9.3.2.3. Regulatory Framework
- 9.3.2.4. UK Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3.3. Germany
- 9.3.3.1. Key Country Dynamics
- 9.3.3.2. Competitive Scenario
- 9.3.3.3. Regulatory Framework
- 9.3.3.4. Germany Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3.4. France
- 9.3.4.1. Key Country Dynamics
- 9.3.4.2. Competitive Scenario
- 9.3.4.3. Regulatory Framework
- 9.3.4.4. France Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3.5. Italy
- 9.3.5.1. Key Country Dynamics
- 9.3.5.2. Competitive Scenario
- 9.3.5.3. Regulatory Framework
- 9.3.5.4. Italy Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3.6. Spain
- 9.3.6.1. Key Country Dynamics
- 9.3.6.2. Competitive Scenario
- 9.3.6.3. Regulatory Framework
- 9.3.6.4. Spain Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3.7. Denmark
- 9.3.7.1. Key Country Dynamics
- 9.3.7.2. Competitive Scenario
- 9.3.7.3. Regulatory Framework
- 9.3.7.4. Denmark Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3.8. Sweden
- 9.3.8.1. Key Country Dynamics
- 9.3.8.2. Competitive Scenario
- 9.3.8.3. Regulatory Framework
- 9.3.8.4. Sweden Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.3.9. Norway
- 9.3.9.1. Key Country Dynamics
- 9.3.9.2. Competitive Scenario
- 9.3.9.3. Regulatory Framework
- 9.3.9.4. Norway Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.4. Asia Pacific
- 9.4.1. Asia Pacific Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.4.2. Japan
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Competitive Scenario
- 9.4.2.3. Regulatory Framework
- 9.4.2.4. Japan Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.4.3. China
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Competitive Scenario
- 9.4.3.3. Regulatory Framework
- 9.4.3.4. China Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.4.4. India
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Competitive Scenario
- 9.4.4.3. Regulatory Framework
- 9.4.4.4. India Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.4.5. Australia
- 9.4.5.1. Key Country Dynamics
- 9.4.5.2. Competitive Scenario
- 9.4.5.3. Regulatory Framework
- 9.4.5.4. Australia Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.4.6. Thailand
- 9.4.6.1. Key Country Dynamics
- 9.4.6.2. Competitive Scenario
- 9.4.6.3. Regulatory Framework
- 9.4.6.4. Thailand Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.4.7. South Korea
- 9.4.7.1. Key Country Dynamics
- 9.4.7.2. Competitive Scenario
- 9.4.7.3. Regulatory Framework
- 9.4.7.4. South Korea Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.5. Latin America
- 9.5.1. Latin America Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.5.2. Brazil
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Competitive Scenario
- 9.5.2.3. Regulatory Framework
- 9.5.2.4. Brazil Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.5.3. Argentina
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Competitive Scenario
- 9.5.3.3. Regulatory Framework
- 9.5.3.4. Argentina Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.6. MEA
- 9.6.1. MEA Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.6.2. South Africa
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Competitive Scenario
- 9.6.2.3. Regulatory Framework
- 9.6.2.4. South Africa Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.6.3. Saudi Arabia
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Competitive Scenario
- 9.6.3.3. Regulatory Framework
- 9.6.3.4. Saudi Arabia Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.6.4. UAE
- 9.6.4.1. Key Country Dynamics
- 9.6.4.2. Competitive Scenario
- 9.6.4.3. Regulatory Framework
- 9.6.4.4. UAE Vascularized Organoids Market, 2021 - 2033 (USD Million)
- 9.6.5. Kuwait
- 9.6.5.1. Key Country Dynamics
- 9.6.5.2. Competitive Scenario
- 9.6.5.3. Regulatory Framework
- 9.6.5.4. Kuwait Vascularized Organoids Market, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Company Categorization
- 10.2. Company Market Share/ Position Analysis, 2025
- 10.3. Strategy Mapping
- 10.4. Company Profiles/Listing
- 10.4.1. Thermo Fisher Scientific Inc.
- 10.4.1.1. Overview
- 10.4.1.2. Financial Performance
- 10.4.1.3. Product Benchmarking
- 10.4.1.4. Strategic Initiatives
- 10.4.2. Corning Incorporated
- 10.4.2.1. Overview
- 10.4.2.2. Financial Performance
- 10.4.2.3. Product Benchmarking
- 10.4.2.4. Strategic Initiatives
- 10.4.3. STEMCELL Technologies
- 10.4.3.1. Overview
- 10.4.3.2. Financial Performance
- 10.4.3.3. Product Benchmarking
- 10.4.3.4. Strategic Initiatives
- 10.4.4. Emulate, Inc.
- 10.4.4.1. Overview
- 10.4.4.2. Financial Performance
- 10.4.4.3. Product Benchmarking
- 10.4.4.4. Strategic Initiatives
- 10.4.5. CN Bio Innovations
- 10.4.5.1. Overview
- 10.4.5.2. Financial Performance
- 10.4.5.3. Product Benchmarking
- 10.4.5.4. Strategic Initiatives
- 10.4.6. MIMETAS
- 10.4.6.1. Overview
- 10.4.6.2. Financial Performance
- 10.4.6.3. Product Benchmarking
- 10.4.6.4. Strategic Initiatives
- 10.4.7. InSphero AG
- 10.4.7.1. Overview
- 10.4.7.2. Financial Performance
- 10.4.7.3. Product Benchmarking
- 10.4.7.4. Strategic Initiatives
- 10.4.8. TissUse GmbH
- 10.4.8.1. Overview
- 10.4.8.2. Financial Performance
- 10.4.8.3. Product Benchmarking
- 10.4.8.4. Strategic Initiatives
- 10.4.9. AIM Biotech
- 10.4.9.1. Overview
- 10.4.9.2. Financial Performance
- 10.4.9.3. Product Benchmarking
- 10.4.9.4. Strategic Initiatives
- 10.4.10. Vivodyne
- 10.4.10.1. Overview
- 10.4.10.2. Financial Performance
- 10.4.10.3. Product Benchmarking
- 10.4.10.4. Strategic Initiatives
- 10.4.1. Thermo Fisher Scientific Inc.
